Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Loxenatide

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

Company n/r · Phase 2/3 · Completed · Enrollment 30

NCT05172999

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
LNG-IUSn/rn/rn/rn/r
LOX+LNG-IUSn/rn/rn/rn/r

Not shown

  • LNG-IUS: endpoint not reported
  • LOX+LNG-IUS: endpoint not reported